---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-008446"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2023-11-24T23:59:59+00:00"
generated_at: "2026-06-07T21:47:24.069891+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte grants $100K cash and 170K options to CEO, $50K cash and 85K options to CFO

## Summary
- One-time grant to Joshua Silverman (Interim CEO): $100,000 cash and options to purchase 170,000 shares at $2.18/share.
- One-time grant to Carlos Trujillo (CFO): $50,000 cash and options to purchase 85,000 shares at $2.18/share.
- Options vest 50% on grant date (Nov 20, 2023) and 50% on one-year anniversary.
- Grants made under the PharmaCyte Biotech 2022 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001683168-23-008446
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2023-11-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316823008446/0001683168-23-008446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316823008446/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-008446
- JSON: https://secwatch.observer/filing/0001683168-23-008446.json
- Plain text: https://secwatch.observer/filing/0001683168-23-008446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.